Mass spectrometric quantification of AcSDKP-NH2 in human plasma and urine and comparison with an immunoassay

Rapid Communications in Mass Spectrometry

Volumn 26, Issue 2, 2012, Pages 163-172

  Mesmin, Cédric ^a   Cholet, Sophie ^a   Blanchard, Anne ^b,c,d   Chambon, Yann ^b,c   Azizi, Michel ^b,c,d   Ezan, Eric ^a  

^a SERVICE DE CHIMIE BIOORGANIQUE ET DE MARQUAGE   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BODY FLUIDS; EXTRACTION; HYDROPHILICITY; IMMUNOLOGY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETERS; MASS SPECTROMETRY; PHASE SEPARATION;

CHROMATOGRAPHIC SEPARATIONS; CHRONIC KIDNEY DISEASE; CLINICAL STUDY; ENZYME IMMUNOASSAY; GLOMERULAR FILTRATION RATE; HUMAN PLASMAS; HUMAN URINE; IN-VIVO; LC-MS-MS; TETRA PEPTIDE;

ELECTROSPRAY IONIZATION;

EID: 83755172207     PISSN: 09514198     EISSN: 10970231     Source Type: Journal    
DOI: 10.1002/rcm.5326     Document Type: Article

References (30)

1. C. Y. Hsu, E. Vittinghoff, F. Lin, M. G. Shlipak,. The incidence of end-stage renal disease is increasing faster than the prevalence of chronic renal insufficiency. Ann. Intern. Med. 2004, 141, 95.
2. A. S. Levey, K. U. Eckardt, Y. Tsukamoto, A. Levin, J. Coresh, J. Rossert, Z. D. De, T. H. Hostetter, N. Lameire, G. Eknoyan,. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005, 67, 2089.
3. A. Whaley-Connell, R. Nistala, K. Chaudhary,. The importance of early identification of chronic kidney disease. Mo. Med. 2011, 108, 25.
4. A. S. Levey,. Use of glomerular filtration rate measurements to assess the progression of renal disease. Semin. Nephrol. 1989, 9, 370.
5. K. H. Rahn, S. Heidenreich, D. Bruckner,. How to assess glomerular function and damage in humans. J. Hypertens. 1999, 17, 309.
6. M. Lenfant, K. Itoh, H. Sakoda, D. Sotty, N. A. Sasaki, J. Wdzieczak-Bakala, K. J. Mori,. Enhancement of the adherence of hematopoietic stem cells to mouse bone marrow-derived stromal cell line MS-1-T by a tetrapeptide acetyl-N-Ser-Asp-Lys-Pro. Exp. Hematol. 1989, 17, 898.
7. M. Azizi, C. Junot, E. Ezan, J. Menard,. Angiotensin I-converting enzyme and metabolism of the haematological peptide N-acetyl-seryl-aspartyl-lysyl- proline. Clin. Exp. Pharmacol. Physiol. 2001, 28, 1066.
8. A. Rousseau, A. Michaud, M. T. Chauvet, M. Lenfant, P. Corvol,. The hemoregulatory peptide N-acetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of the N-terminal active site of human angiotensin-converting enzyme. J. Biol. Chem. 1995, 270, 3656.
9. M. Azizi, A. Rousseau, E. Ezan, T. T. Guyene, S. Michelet, J. M. Grognet, M. Lenfant, P. Corvol, J. Menard,. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. J. Clin. Invest. 1996, 97, 839.
10. M. Azizi, E. Ezan, J. L. Reny, J. Wdzieczak-Bakala, V. Gerineau, J. Menard,. Renal and metabolic clearance of N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) during angiotensin-converting enzyme inhibition in humans. Hypertension 1999, 33, 879.
11. J. Thierry, C. Grillon, S. Gaudron, P. Potier, A. Riches, J. Wdzieczak-Bakala,. Synthesis and biological evaluation of analogues of the tetrapeptide N-Acetyl-Ser-Asp-Lys-Pro (AcSDKP), an inhibitor of primitive haematopoietic cell proliferation. J. Pept. Sci. 2001, 7, 284.
12. M. Azizi, A. Herbet, E. Ezan,. A stable amide analog of the natural haematological tetrapeptide N-acetyl-seryl-aspartyl-lysyl-proline as a new index of glomerular filtration rate: A pre-clinical study. J. Hypertens. 2004, 22, S80.
13. A. N. Hoofnagle, M. H. Wener,. The fundamental flaws of immunoassays and potential solutions using tandem mass spectrometry. J. Immunol. Methods 2009, 347, 3.
14. J. Tate, G. Ward,. Interferences in immunoassay. Clin. Biochem. Rev. 2004, 25, 105.
15. C. M. Preissner, D. J. O'Kane, R. J. Singh, J. C. Morris, S. K. Grebe,. Phantoms in the assay tube: heterophile antibody interferences in serum thyroglobulin assays. J. Clin. Endocrinol. Metab. 2003, 88, 3069.
16. E. Ezan, A. Emmanuel, D. Valente, J. M. Grognet,. Effect of variability of plasma interferences on the accuracy of drug immunoassays. Ther. Drug Monit. 1997, 19, 212.
17. R. Huttenhain, J. Malmstrom, P. Picotti, R. Aebersold,. Perspectives of targeted mass spectrometry for protein biomarker verification. Curr. Opin. Chem. Biol. 2009, 13, 518.
18. M. Ewles, L. Goodwin,. Bioanalytical approaches to analyzing peptides and proteins by LC-MS/MS. Bioanalysis 2011, 3, 1379.
19. C. Mesmin, F. Fenaille, E. Ezan, F. Becher,. MS-based approaches for studying the pharmacokinetics of protein drugs. Bioanalysis 2011, 3, 477.
20. B. Eyrich, A. Sickmann, R. P. Zahedi,. Catch me if you can: mass spectrometry-based phosphoproteomics and quantification strategies. Proteomics 2011, 11, 554.
21. I. van den Broek, R. W. Sparidans, J. H. Schellens, J. H. Beijnen,. Quantitative bioanalysis of peptides by liquid chromatography coupled to (tandem) mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2008, 872, 1.
22. C. Mesmin, M. Dubois, F. Becher, F. Fenaille, E. Ezan,. Liquid chromatography/tandem mass spectrometry assay for the absolute quantification of the expected circulating apelin peptides in human plasma. Rapid Commun. Mass Spectrom. 2010, 24, 2875.
23. C. Junot, F. Theodoro, J. Thierry, G. Clement, J. Wdzieczak-Bakala, E. Ezan,. Development of an enzyme immunoassay for a stable amidated analog of the hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro. J. Immunoassay Immunochem. 2001, 22, 15.
24. A. S. Levey, J. P. Bosch, J. B. Lewis, T. Greene, N. Rogers, D. Roth,. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann. Intern. Med. 1999, 130, 461.
25. I. A. Papayannopoulos,. The interpretation of collision-induced dissociation tandem mass spectra of peptides. Mass Spec. Rev. 1995, 14, 49.
26. F. Fenaille, J. C. Tabet, P. A. Guy,. Study of peptides containing modified lysine residues by tandem mass spectrometry: precursor ion scanning of hexanal-modified peptides. Rapid Commun. Mass Spectrom. 2004, 18, 67.
27. K. Inoue, A. Ikemura, Y. Tsuruta, K. Watanabe, K. Tsutsumiuchi, T. Hino, H. Oka,. Quantification of N-acetyl-seryl-aspartyl-lysyl-proline in hemodialysis patients administered angiotensin-converting enzyme inhibitors by stable isotope dilution liquid chromatography-tandem mass spectrometry. J. Pharm. Biomed. Anal. 2011, 54, 765.
28. K. Inoue, A. Ikemura, Y. Tsuruta, K. Tsutsumiuchi, T. Hino, H. Oka,. On-line solid-phase extraction LC-MS/MS for the determination of Ac-SDKP peptide in human plasma from hemodialysis patients. Biomed. Chromatogr. 2011. DOI: 10.1002/bmc.1636.
29. J. W. Lee, R. S. Weiner, J. M. Sailstad, R. R. Bowsher, D. W. Knuth, P. J. O'Brien, J. L. Fourcroy, R. Dixit, L. Pandite, R. G. Pietrusko, H. D. Soares, V. Quarmby, O. L. Vesterqvist, D. M. Potter, J. L. Witliff, H. A. Fritche, T. O'Leary, L. Perlee, S. Kadam, J. A. Wagner,. Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development: a conference report. Pharm. Res. 2005, 22, 499.
30. J. W. Lee, M. Hall,. Method validation of protein biomarkers in support of drug development or clinical diagnosis/prognosis. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2009, 877, 1259.